Hadassah

Hadassah Collaborates with Columbia University to Identify Treatment for Alopecia

Friday, Jun 5 2015

Working in collaboration with Columbia University, a team of Hadassah Medical Organization physicians have discovered that an arthritis medication may be the solution to baldness caused by alopecia.

The researchers have found that Baricitinib, a medicine in development for treatment of rheumatoid arthritis, may prove effective for severe Alopecia Areata (AA), a common autoimmune disease which causes sudden or gradual hair loss. "Despite its high prevalence," the team reports, "there are no Food and Drug Administration-approved treatments for AA."

The team, including Hadassah Dermatologist Dr. Yuval Ramot, Prof. Abraham Zlotogorski, Director of Hadassah Hospital Ein Kerem's Department of Dermatology and its Hair Loss Clinic, and Prof. Yackov Berkun of Hadassah Hospital Mount Scopus' Pediatric Unit, has found the medicine to be effective in both animals and humans.

"This discovery opens a variety of options for future treatment of AA," notes Dr. Ramot. "That said, extensive clinical trials are still needed in order to fully confirm the findings, before marketing these new medications for treatment of AA."

The research team hopes to begin such clinical trials in the near future. The present study is highlighted in the April 2015 issue of EBioMedicine.

Comments

From: Marjorie on June 6, 2015
I believe I would be a candidate for these clinical trials. Please contact me.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Aug 16 2017

Gazan Boy Walks for First Time at Hadassah

Unable to stand on his feet, suffering from severe respiratory distress, a four-year-old boy from Gaza gained the ability to walk once Hadassah Hospital surgeons identified and removed a large tumor lodged in his chest.

READ MORE ›
alt_text

Wednesday, Aug 16 2017

Hadassah Hosts Health Innovation Conference

Over one hundred doctors, researchers, and entrepreneurs gathered at Hadassah Hospital Ein Kerem this summer to discuss how to advance the quality of patient care with computational power.

READ MORE ›
alt_text

Monday, Aug 14 2017

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

READ MORE ›
alt_text

Thursday, Aug 3 2017

Mystery of Devastating Pediatric Disease Solved by Hadassah Team

A genetic mutation causing a rare and devastating pediatric neurological disease that has puzzled medical centers around the world has been identified at the Hadassah Medical Organization by Prof. Orly Elpeleg, head of Hadassah's Department of Genetics and Metabolic Diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More